Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
We observed an unexpectedly rapid rise in platelet counts with complete haematological recovery after a BEAM regimen, in a patient who could not be rescued by autologous transplant but who received filgrastim, epoetin alfa, and ancestim. We feel that these results may be attributed to this specific growth factor combination, including ancestim, a cytokine known to act on primitive stem cells. If confirmed, this observation may open new possibilities in intensive chemotherapy for patients for whom haematopoietic progenitors are difficult to harvest. This may also represent an alternative to ex-vivo expansion and deserves further investigation.
Blaise
D
D
Faucher
C
C
Vey
N
N
Caraux
J
J
Maraninchi
D
D
Chabannon
C
C
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001772:Blood Cell Count; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D000068817:Epoetin Alfa; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects*; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins; D003561:Cytarabine; D004921:Erythropoietin; D000068817:Epoetin Alfa; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C082430:molgramostim; D008558:Melphalan; D002330:Carmustine